Tests dulaglutide for blood vessel health in type 1 diabetes
Tests dulaglutide against placebo in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Key facts
- Where
- Orlando, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT05478707, who can take part
Where in United States
- AdventHealth Translational Research InstituteOrlando, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AdventHealth Translational Research Institute
- Trial code
- NCT05478707
- Record updated
- 15 October 2026
- Original description
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.Read full original descriptionShow less
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Inclusion: History of type 1 diabetes, duration > 5 years; Age 18-40 years; HbA1c < 8.5%; BMI 19-34.9 kg/m2; Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation); On stable regimen of non-diabetic medications for the last 6 months; All screening labs within normal limits or not clinically significant - English or Spanish speaking.
Exclusion: History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders; Known hypersensitivity to perflutren (contained in Definity© contrast); Musculoskeletal condition preventing participation in exercise testing or exercise training; Acute or unstable disease other than T1D; History of gastroparesis, severe gastroesophageal reflux, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2; Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers); Anemia (hemoglobin <12 g/dL in women, hemoglobin <13 g/dL in men), eosinophilia (absolute eosinophil count >500 cells/microliter) leukopenia (total white blood cells <4,000 cells/microliter); Pregnancy or currently breastfeeding; Smoking history within 6 months; Screening O2 saturation <90%; Hypoglycemia unawareness; Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days; Hospital admission for DKA within 1 year.